Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.35 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14890257 | 1.00 | RNPEP (0.52) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL244272 | 1.00 | RNPEP (0.52) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| Hydrochloric Acid SCHEMBL3050176 | 0.98 | RNPEP (0.50) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL11161410 | 0.84 | RNPEP (0.46) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL23182436 | 0.84 | RNPEP (0.46) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL3047828 | 0.83 | RNPEP (0.44) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL3047827 | 0.83 | RNPEP (0.44) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL7365108 | 0.81 | RNPEP (0.43) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL18125957 | 0.81 | RNPEP (0.43) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL7368232 | 0.81 | RNPEP (0.43) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101947-A1 | MULTIPLEXED TARGETED PEPTIDE QUANTITATION | Astrin Biosciences, Inc. (US) | 2025-05-15 | — | — | WO | claimed |
| US-20240036055-A1 | Multiplexed DiLeu-Biotin-Azide (DBA) Tag Enabled Isobaric Tandem Orthogonal Proteolysis Activity-Based Protein Profiling (isoBOP-ABPP) Platform For High-Throughput Quantitative Pan-PTM Analysis | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2024-02-01 | — | — | US | claimed |
| CN-110950774-B | Protein quantitative marking reagent and preparation method and application thereof | 北京大学 | 2021-04-13 | — | — | CN | claimed |
| CN-112321490-A | Auxiliary agent and preparation method thereof | 宿迁联盛科技股份有限公司 | 2021-02-05 | — | — | CN | claimed |
| CN-112135812-A | Ketamine derivatives and pharmaceutical compositions thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2020-12-25 | — | — | CN | claimed |
| CN-110950774-A | Protein quantitative marking reagent and preparation method and application thereof | 北京大学 | 2020-04-03 | — | — | CN | claimed |
| CN-105636975-A | Anti-inflammatory tripeptides | DR AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL | 2016-06-01 | — | — | CN | claimed |
| EP-2477962-A1 | PRODRUGS OF GUANFACINE | Shire LLC (US) | 2012-07-25 | — | — | EP | claimed |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | claimed |
| CN-102498094-A | Prodrugs of guanfacine | SHIRE LLC | 2012-06-13 | — | — | CN | claimed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | claimed |
| US-6362174-B1 | ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | claimed |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | RAFFERTY MICHAEL FRANCIS (US) | 2002-03-07 | — | — | US | claimed |
| US-6316440-B1 | TREATMENT OF STROKE, HEAD TRAUMA, CEREBRAL ISCHEMIA, PAIN AND EPILEPSY | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | claimed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | claimed |
| US-6117841-A | USED TO TREAT STROKE, CEREBRAL ISCHEMIA, PAIN, HEAD TRAUMA OR EPILEPSY | WARNER-LAMBERT COMPANY (US) | 2000-09-12 | — | — | US | claimed |
| WO-2000006559-A1 | REDUCED DIPEPTIDE ANALOGUES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | claimed |
| WO-1999055688-A1 | SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | claimed |
| WO-1999007689-A1 | ANILINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1999-02-18 | — | — | WO | claimed |
| WO-1998054123-A1 | SUBSTITUTED PEPTIDYLAMINE CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1998-12-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023249-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | RNPEP 4072/4885SLC7A5 3089/4885CPA1 682/4885 |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | CACNA1E, RYR1, CACNA1B | RNPEP 1628/4885SLC7A5 1111/4885CPA1 239/4885 |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | RNPEP 178/4885SLC7A5 121/4885CPA1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.